Dr. Dimcho Bachvarov received his B.Sc. and M.Sc. degrees from the University of Sofia in 1975-1978. He obtained his Ph.D. degree in 1986 from the Institute of Molecular Biology at the Bulgarian Academy of Science. In 1994, he was appointed as Adjunct Professor at Laval University’s department of Pharmacology. Consecutively, Dr. Bachvarov was promoted to Assistant Professor (1997), Associate Professor (2002), and since 2005 he has been a Full Professor at Laval University’s Department of Molecular Medicine. During his academic career, Dr. Bachvarov has received different Scholarship Awards, with the most representative being the Ernest J.B. Tomlinson Scholarship Award from the Kidney Foundation of Canada and other Scholarship Awards (Junior and Senior) from Fonds de recherche du Québec – Santé (FRQ-S).
His research interests are focused on studying the initiation and progression mechanisms of epithelial ovarian cancer (EOC) and improving treatment for this deadly disease, including the identification of early diagnostic or prognostic EOC markers. Dr. Bachvarov has published over 80 papers, predominantly in the EOC research field, and has received funding from CIHR, NSERC, CFI, FRQ-S, CRS and the Terry-Fox Research Institute (TFRI). He has been a co-founder and an active member of the provincial Réseau de Recherche en Cancer (RRCancer, established in 2000; see http://www.rrcancer.ca/), and since then, he has been a co-Chair of the Research Committee of the RRCancer axis entitled “Research and Solid State Tumour Biobank”. Following the establishment of RRCancer, Dr. Bachvarov was also in charge of the organization for the RRCancer-supported ovarian tumor bank in the Centre de recherche sur le cancer de l’Université Laval and the Hôtel-Dieu de Québec Hospital (the bank currently contains EOC specimens from about 3,000 patients). He is also the Head of the RRCancer Core Genomic Facility in Québec city. This facility is based on the Agilent dual channel detection microarray platform and has all the necessary equipment, complementary software and expertise required to perform different microarray experiments, including global gene expression and microRNA expression analyses, methylation DNA microarray-based analyses, array-CGH/CNV and Chip-on-CHIP analyses. The Core Genomic Facility in Québec city is providing a genomics and bioinformatics service to Canadian and foreign scientists who implement genomics approaches in their research (see: https://www.crc.ulaval.ca/la-recherche/plateformes/).
6, rue McMahon
Canada G1R 2J6
Data not available
Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.Journal Article
J Transl Med, 18 (1), pp. 439, 2020.
LY75 Suppression in Mesenchymal Epithelial Ovarian Cancer Cells Generates a Stable Hybrid EOC Cellular Phenotype, Associated with Enhanced Tumor Initiation, Spreading and Resistance to Treatment in Orthotopic Xenograft Mouse Model.Journal Article
Int J Mol Sci, 21 (14), 2020.
LY75 Ablation Mediates Mesenchymal-Epithelial Transition (MET) in Epithelial Ovarian Cancer (EOC) Cells Associated with DNA Methylation Alterations and Suppression of the Wnt/β-Catenin Pathway.Journal Article
Int J Mol Sci, 21 (5), 2020.
Proteases and their inhibitors as prognostic factors for high-grade serous ovarian cancer.Journal Article
Pathol Res Pract, 215 (6), pp. 152369, 2019, ISSN: 0344-0338.
The polypeptide GALNT6 Displays Redundant Functions upon Suppression of its Closest Homolog GALNT3 in Mediating Aberrant O-Glycosylation, Associated with Ovarian Cancer Progression.Journal Article
Int J Mol Sci, 20 (9), 2019.
Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer.Journal Article
PLoS ONE, 14 (6), pp. e0218621, 2019.
Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.Journal Article
BMC Cancer, 18 (1), pp. 347, 2018.
Altered expression of different GalNAc‑transferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer.Journal Article
Int J Oncol, 51 (6), pp. 1887-1897, 2017, ISSN: 1019-6439.
Hic-5 regulates epithelial to mesenchymal transition in ovarian cancer cells in a TGFβ1-independent manner.Journal Article
Oncotarget, 8 (47), pp. 82506-82530, 2017, ISSN: 1949-2553.
Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits the proliferation, migration, invasion and mediates cell cycle arrest of ovarian cancer cells.Journal Article
Cell Cycle, 16 (7), pp. 693-706, 2017, ISSN: 1538-4101.
- Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
- Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2022-06-13